“76x cash transfers: too good to be true or a (missed) opportunity? An invitation for dialogue on a recent Rethink Priorities Report” by Niek Versteegde, founder GOAL 3, Channelijne (Chan) Hulshof🔹 - EA Forum Podcast (Curated & popular) | Lyssna här

TL;DR

GOAL 3 is a social enterprise that created IMPALA, a patient monitoring and digital platform system for low-resource settings. There is also a GOAL 3 foundation that raises funds to ensure underserved communities will be reached.
A recently completed report from Rethink Priorities calculated IMPALA to have a cost per DALY averted of 7 to 17 dollars in paediatric care and 12 to 30 dollars in neonatal care. This translates to around 76× and 28× unconditional cash transfers respectively for paediatrics and neonates against GiveWell's bar, and roughly 11,700× and 4,400× on Coefficient Giving's scale against their 1,000× bar.
RP corrected for study design and robustness of findings by applying a 60% internal-validity and a 30% external-validity discount to our measured mortality effects, arriving at roughly 12% for paediatric wards and 7% for neonatal units.
RP concluded that even at 1-2% relative reduction, the intervention would still be cost-effective.
The post concludes with an invitation for discussion on what these results mean for further research and scaling of IMPALA.

Introduction

GOAL 3 commissioned the Rethink Priorities Global Health and Development team to provide an external analysis of the impact and cost-effectiveness of our product ‘IMPALA.’ IMPALA is a [...]

---

Outline:

(00:21) TL;DR

(01:42) Introduction

(02:19) Understanding the problem in its context

(04:12) Theory of Change

(05:38) What the RP report tells us

(07:43) Interpretation, strengths and limitations

(09:58) Reasons the estimate may be too low or too high

(11:50) Discussion: What would it take to fund scale-up now? How much more evidence, and of what kind?

(16:22) Next steps

(17:42) I want to read more about IMPALA, where can I do that?